Replication of Human Endogenous Retroviruses in Modern Humans

人内源性逆转录病毒在现代人类中的复制

基本信息

项目摘要

DESCRIPTION (provided by applicant): The functions of the approximately 98% of the human genome that do not encode human cellular proteins remain to be elucidated. Actively replicating endogenous retroviruses entered the human genome millions of years ago and became a stable part of the inherited genetic material, with retroviral elements presently making up approximately 8% of the modern human genome. These viruses subsequently acquired multiple mutations, leading to the widely-held assumption that they are no longer competent to replicate. However, in studying living patients rather than the standard cell lines, we have recently discovered surprising evidence suggesting that in certain patients with cancer HERV-K (HML-2), an endogenous retrovirus that is a relatively recent entrant into the human genome and has been linked to oncogenesis, might still be capable of replication. Replication and transmission of endogenous retroviruses is difficult to prove using standard techniques, however, as these viruses are already present in the genomes of all human cells. Therefore, we have assembled a diverse and expert group of investigators who will test the hypothesis that modern HERV-K (HML-2) can replicate using cutting-edge and complementary techniques. We will use a newly devised molecular system in which antibiotic resistance serves as a surrogate marker to assess whether we can passage virus from the blood of patients in the laboratory. We will also use high-throughput DNA sequencing and Bioinformatics to find full-length functional virus that is present in cancer patients but is not represented in the current draft of the human genome. An infectious clone that is representative of modern HERV-K (HML-2) will be made by using the information gained from the Bioinformatics studies and/or by cloning a full-length virus from the HERV-K RNA found in the blood of patients. This clone will then be tagged with green fluorescent protein and used to directly study replication. Building on our advances using Nuclear Magnetic Resonance (NMR) to visualize spatially correlated dynamics that direct RNA and protein conformational transitions, we will also develop NMR methods to visualize HERV-K (HML-2) replication in vivo. Proof that endogenous retroviruses can still replicate in modern humans will lead to a paradigm shift in thinking about these viruses, and will suggest a role for them in reshaping individual genomes. In addition, as increased expression of chromosomal endogenous retroviral sequences has been linked to cancer and autoimmunity, these findings will be relevant to understanding the pathogenesis of significant diseases. Finally, if replicating, infectious endogenous human retroviruses capable of causing disease can be found in the blood of given individuals, this information will have important implications for the safety of the blood supply.
描述(由申请人提供):不编码人类细胞蛋白的约98%的人类基因组的功能仍有待阐明。活跃复制的内源性逆转录病毒在数百万年前进入人类基因组,并成为遗传物质的稳定部分,逆转录病毒元件目前占现代人类基因组的约8%。这些病毒随后获得了多个突变,导致人们普遍假设它们不再能够复制。然而,在研究活体患者而不是标准细胞系时,我们最近发现了令人惊讶的证据,表明在某些癌症患者中,HERV-K(HML-2),一种内源性逆转录病毒,是一种相对较新的进入人类基因组并与肿瘤发生有关的病毒,可能仍然能够复制。然而,内源性逆转录病毒的复制和传播很难使用标准技术来证明,因为这些病毒已经存在于所有人类细胞的基因组中。因此,我们组建了一个多元化的专家研究小组,他们将测试现代HERV-K(HML-2)可以使用尖端和互补技术复制的假设。我们将使用一种新设计的分子系统,其中抗生素耐药性作为替代标记,以评估我们是否可以在实验室中从患者血液中传代病毒。我们还将使用高通量DNA测序和生物信息学来寻找存在于癌症患者中但未在当前人类基因组草案中表示的全长功能性病毒。将使用从生物信息学研究中获得的信息和/或通过从患者血液中发现的HERV-K RNA克隆全长病毒,制备代表现代HERV-K(HML-2)的感染性克隆。然后将该克隆用绿色荧光蛋白标记并用于直接研究复制。基于我们使用核磁共振(NMR)可视化指导RNA和蛋白质构象转变的空间相关动力学的进展,我们还将开发NMR方法来可视化HERV-K(HML-2)体内复制。内源性逆转录病毒仍然可以在现代人类中复制的证据将导致对这些病毒的思考范式转变,并将表明它们在重塑个体基因组中的作用。此外,由于染色体内源性逆转录病毒序列的表达增加与癌症和自身免疫有关,这些发现将有助于理解重大疾病的发病机制。最后,如果能够在特定个体的血液中发现能够引起疾病的复制性传染性内源性人类逆转录病毒,则该信息将对血液供应的安全性具有重要意义。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David Michael Markovitz其他文献

David Michael Markovitz的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David Michael Markovitz', 18)}}的其他基金

Molecularly Engineered Lectins for Intranasal Prophylaxis and Treatment of Coronaviruses
用于鼻内预防和治疗冠状病毒的分子工程凝集素
  • 批准号:
    10629566
  • 财政年份:
    2023
  • 资助金额:
    $ 123.18万
  • 项目类别:
DEK and TNF inhibitors in juvenile arthritis
DEK 和 TNF 抑制剂治疗幼年关节炎
  • 批准号:
    8311059
  • 财政年份:
    2009
  • 资助金额:
    $ 123.18万
  • 项目类别:
Replication of Human Endogenous Retroviruses in Modern Humans
人内源性逆转录病毒在现代人类中的复制
  • 批准号:
    7762721
  • 财政年份:
    2009
  • 资助金额:
    $ 123.18万
  • 项目类别:
DEK and TNF inhibitors in juvenile arthritis
DEK 和 TNF 抑制剂治疗幼年关节炎
  • 批准号:
    8130630
  • 财政年份:
    2009
  • 资助金额:
    $ 123.18万
  • 项目类别:
DEK and TNF inhibitors in juvenile arthritis
DEK 和 TNF 抑制剂治疗幼年关节炎
  • 批准号:
    7835950
  • 财政年份:
    2009
  • 资助金额:
    $ 123.18万
  • 项目类别:
DEK and TNF inhibitors in juvenile arthritis
DEK 和 TNF 抑制剂治疗幼年关节炎
  • 批准号:
    7938774
  • 财政年份:
    2009
  • 资助金额:
    $ 123.18万
  • 项目类别:
Replication of Human Endogenous Retroviruses in Modern Humans
人内源性逆转录病毒在现代人类中的复制
  • 批准号:
    8119694
  • 财政年份:
    2009
  • 资助金额:
    $ 123.18万
  • 项目类别:
Replication of Human Endogenous Retroviruses in Modern Humans
人内源性逆转录病毒在现代人类中的复制
  • 批准号:
    8550159
  • 财政年份:
    2009
  • 资助金额:
    $ 123.18万
  • 项目类别:
CXC Chemokines and HIV Pathogenesis
CXC 趋化因子和 HIV 发病机制
  • 批准号:
    7160544
  • 财政年份:
    2005
  • 资助金额:
    $ 123.18万
  • 项目类别:
CXC Chemokines and HIV Pathogenesis
CXC 趋化因子和 HIV 发病机制
  • 批准号:
    6946547
  • 财政年份:
    2005
  • 资助金额:
    $ 123.18万
  • 项目类别:

相似海外基金

Ecological and Evolutionary Drivers of Antibiotic Resistance in Patients
患者抗生素耐药性的生态和进化驱动因素
  • 批准号:
    EP/Y031067/1
  • 财政年份:
    2024
  • 资助金额:
    $ 123.18万
  • 项目类别:
    Research Grant
Collaborative Research: Leveraging the interactions between carbon nanomaterials and DNA molecules for mitigating antibiotic resistance
合作研究:利用碳纳米材料和 DNA 分子之间的相互作用来减轻抗生素耐药性
  • 批准号:
    2307222
  • 财政年份:
    2024
  • 资助金额:
    $ 123.18万
  • 项目类别:
    Standard Grant
Molecular Epidemiology of Antibiotic Resistance in Clostridioides difficile
艰难梭菌抗生素耐药性的分子流行病学
  • 批准号:
    502587
  • 财政年份:
    2024
  • 资助金额:
    $ 123.18万
  • 项目类别:
Collaborative Research: Leveraging the interactions between carbon nanomaterials and DNA molecules for mitigating antibiotic resistance
合作研究:利用碳纳米材料和 DNA 分子之间的相互作用来减轻抗生素耐药性
  • 批准号:
    2307223
  • 财政年份:
    2024
  • 资助金额:
    $ 123.18万
  • 项目类别:
    Standard Grant
The roles of a universally conserved DNA-and RNA-binding domain in controlling MRSA virulence and antibiotic resistance
普遍保守的 DNA 和 RNA 结合域在控制 MRSA 毒力和抗生素耐药性中的作用
  • 批准号:
    MR/Y013131/1
  • 财政年份:
    2024
  • 资助金额:
    $ 123.18万
  • 项目类别:
    Research Grant
Determining structural dynamics of membrane proteins in their native environment: focus on bacterial antibiotic resistance
确定膜蛋白在其天然环境中的结构动力学:关注细菌抗生素耐药性
  • 批准号:
    MR/X009580/1
  • 财政年份:
    2024
  • 资助金额:
    $ 123.18万
  • 项目类别:
    Fellowship
CAREER: Systems Microbiology and InterdiscipLinary Education for Halting Environmental Antibiotic Resistance Transmission (SMILE HEART)
职业:阻止环境抗生素耐药性传播的系统微生物学和跨学科教育(SMILE HEART)
  • 批准号:
    2340818
  • 财政年份:
    2024
  • 资助金额:
    $ 123.18万
  • 项目类别:
    Continuing Grant
Reinforcing the battle at the bacterial cell wall: Structure-guided characterization and inhibition of beta-lactam antibiotic resistance signalling mechanisms
加强细菌细胞壁的战斗:β-内酰胺抗生素耐药信号机制的结构引导表征和抑制
  • 批准号:
    480022
  • 财政年份:
    2023
  • 资助金额:
    $ 123.18万
  • 项目类别:
    Operating Grants
The spread of antibiotic resistance in bacteria-plasmid networks
抗生素耐药性在细菌-质粒网络中的传播
  • 批准号:
    BB/X010473/1
  • 财政年份:
    2023
  • 资助金额:
    $ 123.18万
  • 项目类别:
    Fellowship
An RNA Nanosensor for the Diagnosis of Antibiotic Resistance in M. Tuberculosis
用于诊断结核分枝杆菌抗生素耐药性的 RNA 纳米传感器
  • 批准号:
    10670613
  • 财政年份:
    2023
  • 资助金额:
    $ 123.18万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了